β-Thalassemia Intermedia: A Bird’s-Eye View

Beta-thalassemia is due to a defect in the synthesis of the beta-globin chains, leading to alpha/beta imbalance, ineffective erythropoiesis, and chronic anemia. The spectrum of thalassemias is wide, with one end comprising thalassemia minor, which consists of a mild hypochromic microcytic anemia with no obvious clinical manifestations, while on the other end is thalassemia major, characterized by patients who present in their first years of life with profound anemia and regular transfusion requirements for survival. Along the spectrum lies thalassemia intermedia, a term developed to describe patients with manifestations that are neither mild enough nor severe enough to be classified in the spectrum’s extremes. Over the past decade, our understanding of β-thalassemia intermedia has increased tremendously with regards to molecular information as well as pathophysiology. It is now clear that β-thalassemia intermedia has a clinical presentation as well as complications associated with the disease that are different from those of β-thalassemia major. This review is designed to tackle issues related to β-thalassemia intermedia from the basic definition of the disease to paramedical issues, namely the quality of life in these patients. Genetics and pathophysiology are revisited, as well as the complications specific to this disease. These complications include effects on several organ systems, including the cardiovascular, hepatic, endocrine, renal, brain, and skeletal systems. Extramedullary hematopoiesis is also discussed in this article. Risk factors are highlighted and cutoffs are identified to minimize morbidities in β-thalassemia intermedia. Several treatment modalities are considered by shining a light on the pros and cons of each modality, as well as the role of special pharmacological agents in the progress of the disease and its morbidities. Finally, health-related quality of life is discussed in these patients with a direct comparison to the more severe β-thalassemia major.

[1]  D. Weatherall,et al.  The α-thalassemias. , 2014, The New England journal of medicine.

[2]  M. Cappellini,et al.  Prevalence and Risk Factors for Pulmonary Arterial Hypertension in a Large Group of &bgr;-Thalassemia Patients Using Right Heart Catheterization: A Webthal Study , 2014, Circulation.

[3]  Paul Tyan,et al.  β-Thalassemia Intermedia: A Bird's-Eye View β-Talasemi İntermedya: Kuşbakişi , 2014 .

[4]  M. Cappellini,et al.  Deferasirox effectively reduces iron overload in non-transfusion-dependent thalassemia (NTDT) patients: 1-year extension results from the THALASSA study , 2013, Annals of Hematology.

[5]  M. Cappellini,et al.  An update on thalassemia intermedia. , 2013, Lebanese Medical Journal.

[6]  M. Cappellini,et al.  Hepatocellular carcinoma in hepatitis-negative patients with thalassemia intermedia: a closer look at the role of siderosis. , 2013, Annals of hepatology.

[7]  A. Taher,et al.  Prevalence of Depression and Anxiety in Adult Patients with β-Thalassemia Major and Intermedia , 2012, International journal of psychiatry in medicine.

[8]  A. Taher,et al.  Cerebral infarction in β-thalassemia intermedia: breaking the silence. , 2012, Thrombosis research.

[9]  M. Cappellini,et al.  Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia. , 2012, Blood cells, molecules & diseases.

[10]  P. Ricchi,et al.  Splenectomy is a risk factor for developing hyperuricemia and nephrolithiasis in patients with thalassemia intermedia: a retrospective study. , 2012, Blood cells, molecules & diseases.

[11]  A. Taher,et al.  β-thalassemia intermedia: a clinical perspective. , 2012, Cold Spring Harbor perspectives in medicine.

[12]  Vip Viprakasit,et al.  A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. , 2012, Blood.

[13]  C. Cesaretti,et al.  Levels of growth differentiation factor-15 are high and correlate with clinical severity in transfusion-independent patients with β thalassemia intermedia. , 2011, Blood cells, molecules & diseases.

[14]  M. Cappellini,et al.  Elevated liver iron concentration is a marker of increased morbidity in patients with β thalassemia intermedia , 2011, Haematologica.

[15]  D. Weatherall Thalassaemia: the long road from the bedside through the laboratory to the community , 2011, Transfusion medicine.

[16]  Suzanne Koussa,et al.  Health‐related quality of life in adults with transfusion‐independent thalassaemia intermedia compared to regularly transfused thalassaemia major: new insights , 2011, European journal of haematology.

[17]  A. Koren,et al.  Healing of refractory leg ulcer in a patient with thalassemia intermedia and hypercoagulability after 14 years of unresponsive therapy. , 2011, The Israel Medical Association journal : IMAJ.

[18]  E. Neufeld,et al.  Renal dysfunction in patients with thalassaemia , 2011, British journal of haematology.

[19]  E. Neufeld,et al.  A phase 1 dose-escalation study: safety, tolerability, and pharmacokinetics of FBS0701, a novel oral iron chelator for the treatment of transfusional iron overload , 2011, Haematologica.

[20]  J. Jankovic,et al.  Iron chelation and neuroprotection in neurodegenerative diseases , 2011, Journal of Neural Transmission.

[21]  C. Ponticelli,et al.  Renal complications in transfusion-dependent beta thalassaemia. , 2010, Blood reviews.

[22]  A T Taher,et al.  Splenectomy and thrombosis: the case of thalassemia intermedia , 2010, Journal of thrombosis and haemostasis : JTH.

[23]  D. Weatherall Thalassemia: the long road from the bedside through the laboratory to the community , 2010, Nature Medicine.

[24]  C. Hershko Pathogenesis and management of iron toxicity in thalassemia , 2010, Annals of the New York Academy of Sciences.

[25]  Nicolò Zanforlin,et al.  The natural history of thalassemia intermedia , 2010, Annals of the New York Academy of Sciences.

[26]  Raffaella Origa,et al.  BETA THALASSEMIA , 2018, The Professional Medical Journal.

[27]  M. Cappellini,et al.  Age‐related complications in treatment‐naïve patients with thalassaemia intermedia , 2010, British journal of haematology.

[28]  M. Cappellini,et al.  Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion‐independent thalassemia intermedia compared to regularly transfused thalassemia major patients , 2010, American journal of hematology.

[29]  M. Cappellini,et al.  Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. , 2010, Blood.

[30]  A. Taher,et al.  Paraspinal extramedullary hematopoiesis in patients with thalassemia intermedia , 2010, European Spine Journal.

[31]  A. Beydoun,et al.  Asymptomatic brain magnetic resonance imaging abnormalities in splenectomized adults with thalassemia intermedia , 2010, Journal of thrombosis and haemostasis : JTH.

[32]  M. Cappellini,et al.  Iron overload in thalassaemia intermedia: reassessment of iron chelation strategies , 2009, British journal of haematology.

[33]  G. Buchanan,et al.  Vascular complications after splenectomy for hematologic disorders. , 2009, Blood.

[34]  P. Criado,et al.  Prevalence of thrombophilia associated with leg ulcers , 2009, The British journal of dermatology.

[35]  M. Gladwin,et al.  Pulmonary complications of sickle cell disease. , 2008, The New England journal of medicine.

[36]  M. Cappellini,et al.  Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermedia , 2008, Haematologica.

[37]  M. Cappellini,et al.  Thalassemia and hypercoagulability. , 2008, Blood reviews.

[38]  M. Khamaisi,et al.  Renal Parenchymal Hypoxia, Hypoxia Response and the Progression of Chronic Kidney Disease , 2008, American Journal of Nephrology.

[39]  R. Galanello,et al.  No evidence of cardiac iron in 20 never- or minimally-transfused patients with thalassemia intermedia , 2008, Haematologica.

[40]  J. Freyssinet,et al.  Elevated levels of circulating procoagulant microparticles in patients with β-thalassemia intermedia , 2008, Haematologica.

[41]  M. Cappellini,et al.  Guidelines for the Clinical Management of Thalassaemia , 2008 .

[42]  C. Borgna-Pignatti Modern treatment of thalassaemia intermedia , 2007, British journal of haematology.

[43]  T. Ganz,et al.  Liver iron concentrations and urinary hepcidin in beta-thalassemia. , 2007, Haematologica.

[44]  T. Ganz,et al.  Liver iron concentrations and urinary hepcidin in β-thalassemia , 2007 .

[45]  A. Phrommintikul,et al.  Splenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia , 2006, Heart.

[46]  M. Cappellini,et al.  Prevalence of thromboembolic events among 8,860 patients with thalassaemia major and intermedia in the Mediterranean area and Iran , 2006, Thrombosis and Haemostasis.

[47]  M. Cappellini,et al.  Thalassemia intermedia: revisited. , 2006, Blood cells, molecules & diseases.

[48]  M. Tsironi,et al.  Extramedullary Hematopoiesis-Related Pleural Effusion: The Case of β-Thalassemia , 2006 .

[49]  S. Perrotta,et al.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. , 2006, Blood.

[50]  M. Nangaku Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. , 2005, Journal of the American Society of Nephrology : JASN.

[51]  M. Cappellini,et al.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with -thalassemia , 2006 .

[52]  E. Vichinsky,et al.  Quality of Life in Patients with Thalassemia Intermedia Compared to Thalassemia Major , 2005, Annals of the New York Academy of Sciences.

[53]  T. Coates,et al.  MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.

[54]  M. Karimi,et al.  Hematologic and Clinical Responses of Thalassemia Intermedia Patients to Hydroxyurea During 6 Years of Therapy in Iran , 2005, Journal of pediatric hematology/oncology.

[55]  M. Kabra,et al.  Hydroxyurea in thalassemia intermedia—a promising therapy , 2005, Annals of Hematology.

[56]  M. Cappellini Overcoming the challenge of patient compliance with iron chelation therapy. , 2005, Seminars in hematology.

[57]  M. Kabra,et al.  Do alpha deletions influence hydroxyurea response in thalassemia intermedia? , 2005, Hematology.

[58]  T. S. St. Pierre,et al.  Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. , 2005, Blood.

[59]  D. Weatherall History of genetic disease: Thalassaemia: the long road from bedside to genome , 2004, Nature Reviews Genetics.

[60]  Asha Shah,et al.  Thalassemia syndromes. , 2004, Indian journal of medical sciences.

[61]  Tetsuhiro Tanaka,et al.  Hypoxia-induced apoptosis in cultured glomerular endothelial cells: involvement of mitochondrial pathways. , 2003, Kidney international.

[62]  S. Chuncharunee,et al.  Pulmonary Arterial Hypertension in Previously Splenectomized Patients with β-Thalassemic Disorders , 2003 .

[63]  A. Hoffbrand,et al.  Clinical trial of deferiprone iron chelation therapy in β‐thalassaemia/haemoglobin E patients in Thailand , 2003, British journal of haematology.

[64]  M. Gladwin,et al.  Nitric oxide's reactions with hemoglobin: a view through the SNO-storm , 2003, Nature Medicine.

[65]  P. Malasit,et al.  Renal tubular dysfunction in α-thalassemia , 2003, Pediatric Nephrology.

[66]  P. Malasit,et al.  Renal tubular dysfunction in alpha-thalassemia. , 2003, Pediatric nephrology (Berlin, West).

[67]  M. Treadwell,et al.  Improving adherence with deferoxamine regimens for patients receiving chronic transfusion therapy. , 2001, Seminars in hematology.

[68]  J. Norman,et al.  Hypoxia promotes fibrogenesis in human renal fibroblasts. , 2000, Kidney international.

[69]  M. Cappellini,et al.  Venous thromboembolism and hypercoagulability in splenectomized patients with thalassaemia intermedia. , 2000, British journal of haematology.

[70]  F. Strutz,et al.  Role of fibroblast activation in inducing interstitial fibrosis. , 2000, Journal of nephrology.

[71]  E. Giarratano,et al.  MR imaging of the brain: findings in asymptomatic patients with thalassemia intermedia and sickle cell-thalassemia disease. , 1999, AJR. American journal of roentgenology.

[72]  J. Norman,et al.  Hypoxia-Induced Changes in Extracellular Matrix Metabolism in Renal Cells , 1999, Nephron Experimental Nephrology.

[73]  C. Koch,et al.  Hypoxia induces renal tubular epithelial cell apoptosis in chronic renal disease. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[74]  A. Cao,et al.  Relationship between Genotype and Phenotype: Thalassemia Intermedia a , 1998, Annals of the New York Academy of Sciences.

[75]  C. Chuang,et al.  Adrenal extramedullary hematopoietic tumor in a patient with beta-thalassemia. , 1998, Journal of the Formosan Medical Association = Taiwan yi zhi.

[76]  B. Brenner,et al.  The hyperfiltration theory: a paradigm shift in nephrology. , 1996, Kidney international.

[77]  Olivieri Nf Reactivation of fetal hemoglobin in patients with beta-thalassemia. , 1996 .

[78]  S. Aggarwal,et al.  Case of the Season , 1995 .

[79]  K. Parsa,et al.  Nonsurgical approach to paraparesis due to extramedullary hematopoiesis. Report of two cases. , 1995, Journal of neurosurgery.

[80]  M. Brezis,et al.  Hypoxia of the renal medulla--its implications for disease. , 1995, The New England journal of medicine.

[81]  M. Cappellini,et al.  Genetic interactions in thalassemia intermedia: analysis of beta-mutations, alpha-genotype, gamma-promoters, and beta-LCR hypersensitive sites 2 and 4 in Italian patients. , 1995, American journal of hematology.

[82]  L. N. de Tilly,et al.  Case of the season. Thalassemia major with extramedullary hematopoiesis in the liver. , 1995, Seminars in roentgenology.

[83]  M. Cappellini,et al.  Thalassemia intermedia. , 1995, Haematologica.

[84]  S. Hmida,et al.  Red cell alloantibodies in patients with haemoglobinopathies. , 1994, Nouvelle revue francaise d'hematologie.

[85]  G. Barosi,et al.  Serum erythropoietin and erythropoiesis in high- and low-fetal hemoglobin beta-thalassemia intermedia patients. , 1994, Blood.

[86]  R. Lifeso,et al.  Combined radiotherapeutic and surgical management of a spinal cord compression by extramedullary hematopoiesis in a patient with hemoglobin E beta-thalassemia. , 1994, Acta haematologica.

[87]  F. Cossu,et al.  Recurrence of spinal cord compression from extramedullary hematopoiesis in thalassemia intermedia treated with low doses of radiotherapy , 1993, American journal of hematology.

[88]  E. Richter [Extramedullary hematopoiesis with intraspinal extension in thalassemia]. , 1993, Aktuelle Radiologie.

[89]  G. Papa,et al.  Incidence and clinical study of ectopic erythropoiesis in adult patients with thalassemia intermedia. , 1992, Annali italiani di medicina interna : organo ufficiale della Societa italiana di medicina interna.

[90]  A. Sumiyoshi,et al.  Pulmonary microthromboemboli in thalassemic cases. , 1992, The Southeast Asian journal of tropical medicine and public health.

[91]  A. Hohimer,et al.  Hemodynamics and organ blood flow in fetal sheep subjected to chronic anemia. , 1991, The American journal of physiology.

[92]  B. Brenner,et al.  Anemia: a potent modulator of renal hemodynamics in models of progressive renal disease. , 1991, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[93]  J. Peristeri,et al.  Red Cell Alloantibodies in Patients with Thalassemia , 1990, Vox sanguinis.

[94]  B. Halliwell,et al.  Role of free radicals and catalytic metal ions in human disease: an overview. , 1990, Methods in enzymology.

[95]  D. Loukopoulos,et al.  Prevention of thalassemia. , 1983, Schweizerische medizinische Wochenschrift.

[96]  M. Pippard,et al.  Ferrioxamine excretion in iron-loaded man. , 1982, Blood.

[97]  E. Rachmilewitz,et al.  Juvenile leg ulceration in beta-thalassemia major and intermedia. , 1982, Plastic and reconstructive surgery.

[98]  S. Fucharoen,et al.  Pulmonary artery obstruction in thalassaemia. , 1980, The Southeast Asian journal of tropical medicine and public health.

[99]  F. Mastrangelo,et al.  Function of the kidney in adult patients with Cooley's disease. A preliminary report. , 1975, Nephron.

[100]  P. Ross,et al.  Roentgen findings in extramedullary hematopoiesis. , 1969, The American journal of roentgenology, radium therapy, and nuclear medicine.

[101]  J. Clegg,et al.  Globin Synthesis in Thalassaemia: An in vitro Study , 1965, Nature.

[102]  A. Stretton,et al.  Genetic basis of the thalassaemia diseases. , 1959, Nature.

[103]  H. Itano,et al.  Genetic and Biochemical Studies of‘Intermediate’Types of Cooley's Anaemia * , 1955, British journal of haematology.

[104]  G. Whipple,et al.  Mediterranean disease-thalassemia(Erythroblastic anemia of cooley) , 1936 .

[105]  W. S. Thayer,et al.  Extramedullary Hematopoiesis in Anemias , 1928 .